ENvue Medical (FEED)
Electromagnetic feeding-tube navigation systems and therapeutic-ultrasound devices.
Something off on this page? Send us feedback.
Combines ENvue electromagnetic feeding-tube navigation systems and dedicated disposable tubes with NanoVibronix therapeutic-ultrasound devices. Revenue pairs reusable hardware with recurring consumables, while the business is shifting strategically toward hospital enteral care even as PainShield products remain the larger revenue source.
Combines the ENvue System for electromagnetic bedside placement of enteral feeding tubes with NanoVibronix's portable therapeutic-ultrasound portfolio. ENvue's console, field generator, sensors and dedicated ENFit-compatible tubes create a patient-specific body map, show tube position and alert users when the path may enter the airway.
Sells ENvue primarily to U.S. acute-care hospitals, pairing navigation systems with single-use proprietary tubes. The commercial approach centers on direct hospital engagement, clinical education and trained operators; conversions also require demonstrations, evaluations and purchasing approval. PainShield uses reusable controllers and disposable transducers, while UroShield is marketed in Europe for urinary-catheter care.
Depends on FDA-cleared adult use for ENvue, payment and coverage decisions, and commercialization in a business concentrated in the United States. PainShield and its monthly kits remain the larger revenue source during the shift toward enteral navigation, while R&D remains consolidated in Tel Aviv.
Company facts
Categories
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.1M · Total debt $1.3M · Total assets $38.4M · Shareholders' equity $30.8M
- Revenue
- $239.0K
- Operating income
- −$5.5M
- Net income
- −$4.9M
No dividends on record.
| Institutions13 holders · as of Mar 31, 2026 | 0.85% | 6.6K shares | |
| Insiders1 holder · as of Apr 17, 2026 | 2.58% | 20.0K shares | |
| Strategic holders1 holder · as of Feb 5, 2026 | 2.52% | 19.5K shares | |
| Otherremainder | 94.05% | 728.6K shares |
774.7K company shares as of Sep 2, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Christian Michael GlibertInsiderother: No longer a 10% holder | 2.58% | 20,000 | Form 4filed Apr 17, 2026 ↗ |
Bank of America Corp /DE/Strategic10 percent owner | 2.52% | 19,505 | Form 4filed Feb 5, 2026 ↗ |
Geode Capital Management, LLCInstitution | 0.24% | 22,417 | 13Fas of Mar 31, 2026 |
Schonfeld Strategic Advisors LLCInstitution | 0.15% | 13,545 | 13Fas of Mar 31, 2026 |
Advisor Group Holdings, Inc.Institution | 0.11% | 10,000 | 13Fas of Mar 31, 2026 |
| See all 15 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jan 14, 2026 | Christian Michael Glibert | 10 percent owner | +240,000 | $2.67 |
| Feb 2, 2026 | Bank of America Corp /DE/ | 10 percent owner | −2,054 | $3.05 |
- Cardinal Health
Primary rival in guided enteral tube placement and tube consumables.
- electroCore
Wearable non-drug pain therapy alternative through the Quell platform.
- Enovis
Clinic-based therapeutic ultrasound alternative for musculoskeletal pain care.
- Bioventus
Home-use ultrasound option for orthopedic recovery and non-invasive care.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ENvue Medical | $4.07 | −1.21% | $3.2M | — | — | 1.7 | — |
| Cardinal Health | $246.99 | +0.63% | $57.50B | 34.0 | 19.6 | 0.2 | +5.8% |
| electroCore | $9.60 | +6.08% | $85.7M | — | — | 2.3 | +28.0% |
| Enovis | $20.70 | +2.48% | $1.16B | — | 5.3 | 0.5 | +3.2% |
| Bioventus | $14.30 | −0.38% | $973.5M | 18.7 | 17.8 | 1.7 | +3.8% |
| Median | 26.3 | 17.8 | 1.1 | +4.8% |